WORCESTER, Mass., March 3, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) announced today that the first patient has received its immunotherapeutic AE37 vaccine as part of a new combination therapy approach for breast and ovarian cancer patients. This vaccine therapy is designed to activate immune cells that can detect and destroy cancer cells. AE37 is being developed by the Company’s wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The new Phase I clinical trial, being performed at the Mary Crowley Cancer Research Centers (“Mary Crowley”) in Dallas and the Brooke Army Medical Center (“BAMC”) in San Antonio, will assess safety and immunological response in patients with either breast and/ or ovarian cancer. Patients in the study will be clinically cancer free, having completed primary standard of care breast and/or ovarian therapies.
